Kiniksa Pharmaceuticals International, plc financial data

Symbol
KNSA on Nasdaq
Industry
Pharmaceutical Preparations
Location
23 Old Bond Street, Floor 3, London, United Kingdom
State of incorporation
United Kingdom
Fiscal year end
December 31
Former names
Kiniksa Pharmaceuticals, Ltd. (to 6/28/2024)
Latest financial report
10-Q - Q3 2024 - Oct 29, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 376 % -28.9%
Quick Ratio 39.6 % -22.7%
Debt-to-equity 23 % +38.1%
Return On Equity -2.08 % -24.6%
Return On Assets -1.69 % -18.2%
Operating Margin -6.83 % +11.6%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 510M USD +47.2%
Weighted Average Number of Shares Outstanding, Basic 71.7M shares +2.2%
Weighted Average Number of Shares Outstanding, Diluted 71.7M shares +2.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 384M USD +54.4%
Research and Development Expense 96.5M USD +36.9%
Operating Income (Loss) -26.2M USD -36.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -16.7M USD -36.4%
Income Tax Expense (Benefit) -7.66M USD -37.5%
Net Income (Loss) Attributable to Parent -9.07M USD -35.5%
Earnings Per Share, Basic -0.12 USD/shares -9.09%
Earnings Per Share, Diluted -0.12 USD/shares -20%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 97.4M USD -17.4%
Cash, Cash Equivalents, and Short-term Investments 224M USD +11.3%
Accounts Receivable, after Allowance for Credit Loss, Current 24.9M USD +718%
Inventory, Net 28.7M USD +12.1%
Assets, Current 311M USD +21.6%
Deferred Income Tax Assets, Net 208M USD +7.45%
Property, Plant and Equipment, Net 561K USD -38.9%
Operating Lease, Right-of-Use Asset 11.1M USD -12.4%
Other Assets, Noncurrent 7.85M USD +242%
Assets 555M USD +15%
Accounts Payable, Current 8.33M USD +723%
Employee-related Liabilities, Current 13.1M USD +6.64%
Accrued Liabilities, Current 40.4M USD -1.87%
Contract with Customer, Liability, Current 12K USD -99.7%
Liabilities, Current 96M USD +79.5%
Contract with Customer, Liability, Noncurrent 11.8M USD -0.51%
Operating Lease, Liability, Noncurrent 8.56M USD -19.6%
Other Liabilities, Noncurrent 1.96M USD +0.87%
Liabilities 118M USD +51.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -41K USD -4000%
Retained Earnings (Accumulated Deficit) -512M USD -1.8%
Stockholders' Equity Attributable to Parent 437M USD +7.87%
Liabilities and Equity 555M USD +15%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 3.99M USD
Net Cash Provided by (Used in) Financing Activities 3.61M USD +3914%
Net Cash Provided by (Used in) Investing Activities 25.5M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 97.4M USD -17.4%
Deferred Tax Assets, Valuation Allowance 46.3M USD +136%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0 pure
Deferred Tax Assets, Gross 269M USD +30.1%
Operating Lease, Liability 13M USD
Depreciation 596K USD -48.9%
Payments to Acquire Property, Plant, and Equipment 84K USD +250%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -9.11M USD -37.5%
Lessee, Operating Lease, Liability, to be Paid 15.1M USD
Property, Plant and Equipment, Gross 8.67M USD +0.19%
Operating Lease, Liability, Current 2.03M USD -12.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.24M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 2.92M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure
Deferred Income Tax Expense (Benefit) 4.37M USD +305%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.12M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.95M USD
Deferred Tax Assets, Operating Loss Carryforwards 1.13M USD -72.2%
Unrecognized Tax Benefits 1.79M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3M USD
Additional Paid in Capital 949M USD +4.51%
Deferred Tax Assets, Net of Valuation Allowance 219M USD +18.2%
Share-based Payment Arrangement, Expense 30.2M USD +17.2%